Franc Llorens

Summary

Publications

  1. Kanata E, Golanska E, Villar Piqué A, Karsanidou A, Dafou D, Xanthopoulos K, et al. Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease. J Clin Neurosci. 2018;: pubmed publisher
    ..77 to 0.96), respectively. CSF NFL was associated neither to age nor to sex but correlated with total-tau concentrations in both cohorts. Overall, our data provide independent validation of CSF NFL utility in sCJD differential diagnosis. ..
  2. Schmitz M, Villar Piqué A, Llorens F, Gmitterova K, Hermann P, Varges D, et al. Cerebrospinal Fluid Total and Phosphorylated ?-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy. Mol Neurobiol. 2018;: pubmed publisher
    ..In conclusion, our data confirm t-?-synuclein and p-?-synuclein as robust biomarkers for sCJD and indicate the potential use of colorimetric t-?-synuclein ELISAs for differential diagnosis of dementia types. ..
  3. Llorens F, Kruse N, Schmitz M, Shafiq M, da Cunha J, Gotzman N, et al. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD. J Neurol. 2015;262:2305-11 pubmed publisher
    ..Importantly, α-synuclein levels detected by ECL allow an excellent discrimination between sCJD cases and AD and control cases, unveiling a new clinical approach for the differential diagnosis of sCJD. ..
  4. Llorens F, Barrio T, Correia Â, Villar Piqué A, Thune K, Lange P, et al. Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie. Mol Neurobiol. 2018;55:8586-8591 pubmed publisher
    ..Our work also supports the potential use of these tests in the screening of pre-symptomatic scrapie and human prion disease cases. ..
  5. Villar Piqué A, Schmitz M, Lachmann I, Karch A, Calero O, Stehmann C, et al. Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Mol Neurobiol. 2018;: pubmed publisher
    ..Our data indicate that CSF t-PrP concentrations may have a role as a pre-clinical or early symptomatic diagnostic biomarker in prion diseases as well as in the evaluation of therapeutic interventions. ..
  6. Llorens F, Schmitz M, Gloeckner S, Kaerst L, Hermann P, Schmidt C, et al. Increased albumin CSF/serum ratio in dementia with Lewy bodies. J Neurol Sci. 2015;358:398-403 pubmed publisher
    ..The present study demonstrates increased Qalb in synucleinopathies associated with dementia revealing a potential new clinical approach for the differential diagnosis of DLB. ..
  7. Zerr I, Schmitz M, Karch A, Villar Piqué A, Kanata E, Golanska E, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018;14:751-763 pubmed publisher
    ..Increased NFL levels are a common feature in neurodegenerative dementias. ..
  8. Llorens F, Schmitz M, Karch A, Cramm M, Lange P, Gherib K, et al. Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimers Dement. 2016;12:577-89 pubmed publisher
    ..Combining the biomarker panel allows differentiating between various types of neurodegenerative dementias and contributes to a better understanding of their pathophysiological processes. ..
  9. López González I, Garcia Esparcia P, Llorens F, Ferrer I. Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies. Int J Mol Sci. 2016;17:206 pubmed publisher

More Information

Publications16

  1. Llorens F, Schmitz M, Ferrer I, Zerr I. CSF biomarkers in neurodegenerative and vascular dementias. Prog Neurobiol. 2016;138-140:36-53 pubmed publisher
  2. Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, Gmitterova K, et al. Cerebrospinal ?-synuclein in ?-synuclein aggregation disorders: tau/?-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol. 2016;263:2271-2277 pubmed
    ..7739) levels. In conclusion, ?-synuclein alone lacks of clinical value as a biomarker of ?-synuclein-related disorders, but in combination with total tau, it may improve the diagnosis of dementia with Lewy bodies. ..
  3. Llorens F, Kruse N, Schmitz M, Gotzmann N, Golanska E, Thune K, et al. Evaluation of ?-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases. Alzheimers Dement. 2017;13:710-719 pubmed publisher
    ..These data highlight the utility of CSF ?-synuclein quantification in front of classical CSF biomarkers in clinical routine. ..
  4. Llorens F, Kruse N, Karch A, Schmitz M, Zafar S, Gotzmann N, et al. Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease. Mol Neurobiol. 2018;55:2249-2257 pubmed publisher
    ..Additionally, the current test presents some advantages compared to other diagnostic approaches: it is fast, economic, requires minimal amount of CSF and a-syn levels are stable along disease progression. ..
  5. Llorens F, Zarranz J, Fischer A, Zerr I, Ferrer I. Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations. Curr Neurol Neurosci Rep. 2017;17:30 pubmed publisher
    ..Although the development of a therapy is still a major challenge, recent findings represent a step toward understanding of the clinical and molecular aspects of FFI. ..
  6. Llorens F, Thune K, Tahir W, Kanata E, Diaz Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12:83 pubmed publisher
    ..Therefore, YKL-40 quantification might have a potential for application in the evaluation of therapeutic intervention in dementias with a neuroinflammatory component. ..
  7. Llorens F, Thüne K, Sikorska B, Schmitz M, Tahir W, Fernández Borges N, et al. Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease. Acta Neuropathol Commun. 2017;5:35 pubmed publisher
    ..Altogether our work indicates that unbalanced Calpain-Cathepsin activation is a relevant contributor to the pathogenesis of sCJD at multiple molecular levels and a potential target for therapeutic intervention. ..